BusinessWire India
Bengaluru (Karnataka) [India], October 14: As climate change, rapid urbanization and shifting rainfall patterns continue to reshape dengue transmission across India, public health leaders, policymakers, scientists and civil society today convened for "From Awareness to Action: Advancing Dengue Prevention in Karnataka." The multi-stakeholder dialogue culminated in the endorsement of a 4-Point Call-to-Action aimed at transitioning the state from seasonal outbreak response to continuous, year-round dengue preparedness.
The high-level forum was organized with participation from Takeda Biopharmaceuticals India Private Limited ("Takeda"), Mr. U.T. Khader Fareed, Minister for Health and Family Welfare, Government of Karnataka and Mr. Madhu Bangarappa, Minister for School Education and Literacy, Government of Karnataka, alongside more than 20 state government representatives, leading public health institutions, researchers, innovators, academia and civil society organizations.
With over half the world's population remaining at risk for dengue,1 the dialogue comes at a critical moment as dengue continues its transformation from a seasonal outbreak concern into a year-round public health threat. Experts cautioned that lower seasonal case counts must not lead to complacency, as many of the forces driving dengue transmission, including climate change, rising temperatures and urban expansion, continue to intensify.
A Whole-of-Society Strategy Driven by Janabhāgitva
At the event, public health leaders emphasized that dengue cannot be addressed by health systems alone. Effective prevention requires coordination and awareness building across government, education, science, and local communities. The dialogue was anchored in the core Kannada principle of Janabhāgitva (people's participation and shared responsibility), recognizing that dengue prevention starts where people live, study and work.
Mr. U.T. Khader Fareed, Minister for Health and Family Welfare, Government of Karnataka said, "Karnataka's recent decline in dengue cases is encouraging, but it is not a signal to become complacent. The environmental conditions that drive dengue transmission continue to evolve, and future outbreaks remain a real possibility. Our next step is to strengthen how we predict, prevent and manage dengue by exploring new innovations in surveillance, diagnostics, vector monitoring, vaccination and community-based prevention. As scientific understanding advances, Karnataka will continue to evaluate emerging innovations and adopt approaches that are proven to be safe, effective and beneficial for our communities.
The goal is not simply fewer cases this year, but a more resilient Karnataka that is better prepared for the years ahead."
Classrooms as Catalysts that Link Health to Science and Community Action
Highlighting the pivotal role of schools, the Ministry for School Education and Literacy detailed practical school-level dengue awareness and prevention measures already under implementation and outlined a vision to integrate public health into experiential learning.
Mr. Madhu Bangarappa, Minister for School Education and Literacy, Government of Karnataka said, “A government's responsibility is not just to treat cases after they rise but to keep numbers from rising in the first place. Karnataka is known for science, technology, and innovation, and public health must benefit from that strength. Our schools are already leveraging morning assemblies, notice boards, and parent outreach for dengue awareness. When children lead, families listen, and communities become safer. Connecting public health awareness with STEM and eco-clubs allows students to see the real-world value of what they learn.”
Science-Led Partnerships for Long-Term Resilience
Participants agreed that Karnataka's recent progress against dengue should be viewed not as an endpoint, but as an opportunity to strengthen long-term resilience. As environmental and demographic changes continue to increase the risk of future outbreaks, stakeholders emphasized that the most effective defence against dengue will be a coordinated, WHO-recommended science-informed approach that combines prevention, preparedness, innovation, community awareness, public participation and vaccination throughout the year.
Dr. Mahender Nayak, Head of Intercontinental Markets, International Business Unit, Takeda said, " We need to get ahead of dengue through better science, stronger surveillance, earlier detection, wider community awareness and more informed decision-making, including the option of immunization through dengue vaccines. The opportunity before us is to shift dengue management from seasonal response to year-round preparedness. Through partnerships with governments, researchers and healthcare leaders, Takeda is committed to supporting evidence generation, scientific exchange and innovative approaches that can help communities become more resilient to dengue over the long term."
A Strategic 4-Point Blueprint for Dengue Preparedness
Public health experts from ARTPARK, Institute of Health Management & Research, Tata Institute for Genetics and Society, and leading epidemiologists highlighted that dengue remains a complex and evolving public health challenge. While vector control remains essential, experts noted that sustainable control requires a broader and more integrated strategy.
In line with the World Health Organization (WHO) recommendations, participants agreed that surveillance, vector control, early case management, community education, and vaccination must work together as an integrated strategy to reduce long-term disease burden.
Building on the discussions, participants identified 4-Point Call to Action, that could help strengthen Karnataka’s dengue preparedness:
*         Making dengue prevention year-round: Transitioning from monsoon-focused crisis response to continuous, 365-day engagement by integrating behavior change communication (BCC) across schools, workplaces, and communities; prioritizing positive incentives ahead of penalties.
*         Closing the loop of care: Linking community-level screening directly to rapid diagnosis, timely primary healthcare referral, and structured follow-up.
*         Making data work: Harmonizing state and municipal surveillance data, strengthening ward-level analytics, enabling citizen reporting, and ensuring transparent treatment costs.
*         Backing innovation: Funding locally adaptable, youth-driven solutions and tech-enabled vector monitoring through pilot initiatives across Bengaluru and Karnataka.
References
[1] World Health Organization, World Dengue Day 2026, June 15, 2026. https://www.who.int/news-room/events/detail/2026/06/15/default-calendar/world-dengue-day-2026
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than 245 years.
For nearly 30 years, Takeda has been bringing innovative medicines to patients in India, with capabilities spanning R&D, manufacturing, commercial operations and its Global Capability Centre in Bengaluru. Takeda remains committed to supporting India’s evolving healthcare needs and advancing access to innovative medicines and vaccines. For more information, visit www.takeda.com.
Important Notice 
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. 
The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.
Forward-Looking Statements 
This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results. 
Medical Information 
This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. 
(ADVERTORIAL DISCLAIMER: The above press release has been provided by BusinessWire India. ANI will not be responsible in any way for the content of the same)